How did CSCI's revenue and expenses shift in Q3 2024 compared to previous quarters?

Cosciens Biopharma (CSCI) experienced a significant increase in revenue in Q3 2024, with the total revenue reported at $1.87 million compared to $2.34 million in Q2 2024 and $4000 in Q1 2024. However, the total expenses for Q3 2024 are not available. This substantial rise in revenue suggests that CSCI may have had a strong performance or achieved significant milestones during this period, which could be indicative of improved operational efficiency or strategic initiatives. |code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code| |---|---|---|---|---|---|---| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q4|1214000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q1|4000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q2|2337000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q3|1871000||186| |code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code| |---|---|---|---|---|---|---| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q3|1952000||186| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q4|1214000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q1|4000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q2|2337000||186| |code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code| |---|---|---|---|---|---|---| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q2|1392000||186| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q3|1952000||186| |CSCI|CSCI.O|Cosciens Biopharma|2023 Q4|1214000||186| |CSCI|CSCI.O|Cosciens Biopharma|2024 Q1|4000||186|